SMBC Nikko Sticks to Their Hold Rating for Astellas Pharma (ALPMF)
In a report released today, from SMBC Nikko maintained a Hold rating on Astellas Pharma, with a price target of Yen2,000.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to SMBC Nikko, Astellas Pharma also received a Hold from TipRanks – Anthropic’s Anthropic Drug Manufacturers – General in a report issued on February 6. However, on the same day, TipRanks – PerPlexity reiterated a Buy rating on Astellas Pharma (Other OTC: ALPMF).
The company has a one-year high of Yen2,570.00 and a one-year low of Yen1,243.50. Currently, Astellas Pharma has an average volume of 7.89M.
Read More on ALPMF:
Disclaimer & DisclosureReport an Issue
- Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
- Astellas-Backed Bladder Cancer Trial Nears Key Data Moment After Study Completion
- Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
- Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand
- ALPMF Upcoming Earnings Report: What to Expect?
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.